Merck (MRK) Tops Q2 EPS by 12c; Raises Guidance

Merck (NYSE: MRK) reported Q2 EPS of ($2.06), $0.12 better than the analyst estimate of ($2.18). Revenue for the quarter came in at $15 billion versus the consensus estimate of $14.43 billion.

GUIDANCE:

Merck sees FY2023 EPS of $2.95-$3.05, versus the consensus of $2.60. Merck sees FY2023 revenue of $58.6-59.6 billion, versus the consensus of $53.2 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance